18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: Results from neo-ALTTO

Journal of Nuclear Medicine

Volumn 54, Issue 11, 2013, Pages 1862-1868

  Gebhart, Geraldine ^a   Gámez, Cristina ^b   Holmes, Eileen ^c   Robles, Javier ^b   Garcia, Camilo ^a   Cortés, Montserrat ^b   De Azambuja, Evandro ^a,d   Fauria, Karine ^e   Van Dooren, Veerle ^d   Aktan, Gursel ^f   Coccia Portugal, Maria Antonia ^g   Kim, Sung Bae ^h   Vuylsteke, Peter ⁱ   Cure, Hervé ^j   Eidtmann, Holger ^k   Baselga, José ^e,l   Piccart, Martine ^a   Flamen, Patrick ^a   Di Cosimo, Serena ^e,m  

^a JULES BORDET INSTITUTE   (Belgium)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^d Breast European Adjuvant Study Team (BrEAST) Data Centre   (Belgium)

^e SOLTI Breast Cancer Research Group   (Spain)

^f GLAXOSMITHKLINE   (United States)

^g Eastleigh Breast Care Centre   (South Africa)

^h University of Ulsan College of Medicine   (South Korea)

ⁱ Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

^j INSTITUT JEAN GODINOT   (France)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l HARVARD MEDICAL SCHOOL   (United States)

^m NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

Anti HER2 drugs; Early response assessment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; LAPATINIB; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAXIMUM STANDARDIZED UPTAKE VALUE; METABOLIC RATE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT MONITORING; PET SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; TREATMENT RESPONSE; TUMOR VOLUME; 18F-FDG-PET/CT; ADJUVANT THERAPY; ANTI-HER2 DRUGS; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; EARLY RESPONSE ASSESSMENT; METABOLISM; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; BREAST NEOPLASMS; DIAGNOSTIC USE;

18F-FDG-PET/CT; ANTI-HER2 DRUGS; EARLY RESPONSE ASSESSMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; RECEPTOR, ERBB-2; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84890308316     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.119271     Document Type: Article

References (34)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
2. Slamon DJ, Godolphin W, Jone LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
3. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 2000; 27(5, suppl 9):13-19.
4. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353: 1659-1672.
7. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
8. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36.
9. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
10. Johnston S, Pippen J Jr., Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptorpositive metastatic breast cancer. J Clin Oncol. 2009;27:5538-5546.
11. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005;24:6213-6221.
12. Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28:803-814.
13. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124-1130.
14. Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15:429-440.
15. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51.
16. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23:3676-3685.
17. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29:3351-3357.
18. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633-640.
19. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95:681-695.
20. Fox JJ, Autran-Blanc E, Morris MJ, et al. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med. 2011;52:1727-1732.
21. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
22. Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012;30:1989-1995.
23. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32.
24. Gianni LBG, Kiermaier A, Bianchi G, et al. Neoadjuvant pertuzumab and trastuzumab: biomarker analyses of a 4-arm randomized phase II study (Neosphere) in patients with HER2-positive breast cancer. Cancer Res. 2011;71(24 suppl):S5-1.
25. Keam B, Im SA, Koh Y, et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer. 2011;11:452.
26. 18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915-1924.
27. 18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-1695.
28. 18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366-5372.
29. 18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535-541.
30. 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med. 2012;53:249-254.
31. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377-384.
32. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA. 2006;103:7795-7800.
33. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29:217-233.
34. Rimawi MF, Mayer IA, Forero A, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013;31:1726-1731.